Cargando…

Potential benefit of dolutegravir once daily: efficacy and safety

The viral integrase enzyme has recently emerged as a primary alternative target to block HIV-1 replication, and integrase inhibitors are considered a pivotal new class of antiretroviral drugs. Dolutegravir is an investigational next-generation integrase inhibitor showing some novel and intriguing ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fantauzzi, Alessandra, Turriziani, Ombretta, Mezzaroma, Ivano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570074/ https://www.ncbi.nlm.nih.gov/pubmed/23413040 http://dx.doi.org/10.2147/HIV.S27765

Ejemplares similares

The Many Faces of Immune Activation in HIV-1 Infection: A Multifactorial Interconnection
por: Mazzuti, Laura, et al.
Publicado: (2023)

Benefits of once-daily therapies in the treatment of hypertension
por: Flack, John M, et al.
Publicado: (2011)

Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns
por: Falasca, Francesca, et al.
Publicado: (2017)

Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO
por: Molina, Jean-Michel, et al.
Publicado: (2014)

Management of HIV-1 associated hepatitis in patients with acquired immunodeficiency syndrome: role of a successful control of viral replication
por: Esposito, Antonella, et al.
Publicado: (2011)

Usefulness of calcaneal quantitative ultrasound stiffness for the evaluation of bone health in HIV-1-infected subjects: comparison with dual X-ray absorptiometry
por: Fantauzzi, Alessandra, et al.
Publicado: (2016)

Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis
por: Pellicano, Chiara, et al.
Publicado: (2022)

Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis
por: Böhm, Stephan Karl, et al.
Publicado: (2014)

Efficacy and safety of once daily dosing of colistin to critically ill patients
por: Skiada, A, et al.
Publicado: (2010)

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease
por: Jones, Paul W, et al.
Publicado: (2011)

Efficacy and Safety of Terbinafine 500 mg Once Daily in Patients with Dermatophytosis
por: Babu, P Ravindra, et al.
Publicado: (2017)

Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV
por: Kandel, Christopher E, et al.
Publicado: (2015)

Efficacy and safety of once daily tacrolimus compared to twice daily tacrolimus after liver transplantation
por: Bzeizi, Khalid Ibrahim, et al.
Publicado: (2021)

Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma
por: O’Byrne, Paul M., et al.
Publicado: (2016)

A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy
por: Washington, Samuel L, et al.
Publicado: (2010)

Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary
por: Ball, Susan G, et al.
Publicado: (2013)

MicroRNA-29 family expression and its relation to antiviral immune response and viro-immunological markers in HIV-1-infected patients
por: Monteleone, Katia, et al.
Publicado: (2015)

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2017)

A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes
por: Alshali, Khalid Z., et al.
Publicado: (2016)

Review of Efficacy and Safety of Duloxetine 40 to 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain
por: Skljarevski, Vladimir, et al.
Publicado: (2012)

Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme
por: Thethi, Tina K., et al.
Publicado: (2020)

Efficacy and safety of once‐daily insulin degludec/insulin aspart compared with once‐daily insulin glargine in participants with Type 2 diabetes: a randomized, treat‐to‐target study
por: Kumar, S., et al.
Publicado: (2016)

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
por: Petersen, Andreas B, et al.
Publicado: (2013)

Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease
por: Esposito, Antonella, et al.
Publicado: (2011)

Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study
por: Buhl, Roland, et al.
Publicado: (2015)

Efficacy and safety of a switch from twice-daily tacrolimus to once-daily generic tacrolimus in stable liver transplant patients
por: Kim, Jong Man, et al.
Publicado: (2021)

Safety and Efficacy of Once-Daily Gastroretentive Gabapentin in Patients with Postherpetic Neuralgia Aged 75 Years and Over
por: Gupta, Anita, et al.
Publicado: (2013)

Efficacy and Safety of Once Daily Fluticasone Furoate Nasal Spray for Treatment of Irritant (Non-allergic) Rhinitis
por: Tantilipikorn, Pongsakorn, et al.
Publicado: (2010)

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide
por: Wysham, C, et al.
Publicado: (2011)

Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial
por: D'Urzo, Anthony, et al.
Publicado: (2011)

Once-daily dosing of gentamicin.
por: Soper, D E
Publicado: (1998)

Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes
por: Hoimark, Lene, et al.
Publicado: (2012)

Spotlight on grazoprevir–elbasvir once-daily combination and its potential in the treatment of hepatitis C
por: Suraweera, Duminda, et al.
Publicado: (2016)

Humoral and T-cell mediated response after administration of mRNA vaccine BNT162b2 in frail populations
por: Campagna, Roberta, et al.
Publicado: (2022)

Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease
por: Wentrup, Andreas, et al.
Publicado: (2009)

Once-daily medications for the pharmacological management of ADHD in adults
por: Tcheremissine, Oleg V, et al.
Publicado: (2009)

Update on once-daily zonisamide monotherapy in partial seizures
por: Afra, Pegah, et al.
Publicado: (2014)

Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety
por: Derington, Catherine G., et al.
Publicado: (2020)

Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients
por: Radford, Matthew, et al.
Publicado: (2019)

Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice
por: Gooderham, Melinda J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o0ugcf7d3duq6dfqf8bgrkpfr6